Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kyverna Therapeutics Inc KYTX

Healthcare Biotechnology
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune... see more

Recent & Breaking News (NDAQ:KYTX)

KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Business Wire June 14, 2024

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

PR Newswire June 10, 2024

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

PR Newswire June 7, 2024

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

PR Newswire May 14, 2024

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

PR Newswire April 11, 2024

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

PR Newswire March 29, 2024

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

PR Newswire March 26, 2024

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

PR Newswire March 7, 2024

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire February 12, 2024